Maria De Santis
Overview
Explore the profile of Maria De Santis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
10365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401283.
PMID: 40043230
Purpose: The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase III KEYNOTE-921 trial (Clinicaltrials.gov...
2.
Heidenreich A, Bohmer D, Bolenz C, Borkowetz A, Rieger C, De Santis M
Dtsch Arztebl Int
. 2025 Feb;
(Forthcoming).
PMID: 39964043
Background: 17 500 persons receive a new diagnosis of urothelial carcinoma of the bladder in Germany each year. Radical cystectomy is performed for muscle-invasive and for non-muscle-invasive, recurrent, high-risk tumors....
3.
Panebianco V, Catalano C, Sanguedolce F, De Santis M, Padhani A
Eur Radiol
. 2025 Jan;
PMID: 39890618
No abstract available.
4.
Furlano K, Keshavarzian T, Biernath N, Fendler A, De Santis M, Weischenfeldt J, et al.
Int J Cancer
. 2025 Jan;
PMID: 39853587
Prostate cancer is a common malignancy that in 5%-30% leads to treatment-resistant and highly aggressive disease. Metastasis-potential and treatment-resistance is thought to rely on increased plasticity of the cancer cells-a...
5.
Galsky M, Kockx M, Roels J, Van Elzen R, Guan X, Yuen K, et al.
Cancer Immunol Res
. 2025 Jan;
PMID: 39853278
Testing for PD-L1 expression by immunohistochemistry (IHC) is used to predict immune checkpoint blockade (ICB) benefit but has performed inconsistently in urothelial cancer (UC) clinical trials. Different approaches are used...
6.
Rosnev S, Sterner B, Schiele P, Kolling S, Martin M, Florcken A, et al.
Eur J Cancer
. 2025 Jan;
217:115252.
PMID: 39848112
Background: Despite remarkable clinical efficacy, little is known about the system-wide immunological alterations provoked by PD1 blockade. Dynamics of quantitative immune composition and functional repertoire during PD1 blockade could delineate...
7.
Luca G, De Santis M, Batani V, Tonutti A, Campochiaro C, Palmisano A, et al.
Semin Arthritis Rheum
. 2025 Jan;
71:152622.
PMID: 39826307
Background: Primary heart involvement (pHI) is frequent in systemic sclerosis (SSc), and is associated with a poor prognosis. Therapeutic strategies to treat SSc-pHI are not yet defined. Objectives: To evaluate...
8.
Cacciapaglia F, De Angelis R, Ferri C, Bajocchi G, Bellando-Randone S, Bruni C, et al.
J Rheumatol
. 2025 Jan;
PMID: 39814435
Objective: Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU...
9.
Ceribelli A, Tonutti A, Isailovic N, De Santis M, Selmi C
Semin Arthritis Rheum
. 2025 Jan;
71:152619.
PMID: 39798246
Objective: Older age, dermatomyositis, and specific serum autoantibodies such as anti-TIF1-γ are associated with higher cancer risk in patients with myositis. We evaluated a vast cohort of patients with myositis...
10.
Hasaligil A, Munro V, Strunz-McKendry T, Wang-Silvanto J, Milloy N, Unsworth M, et al.
Future Oncol
. 2025 Jan;
21(5):569-578.
PMID: 39789976
Introduction: The treatment landscape of metastatic urothelial carcinoma (mUC) has evolved with the emergence of programmed cell death protein 1/ligand 1 (PD-1/L1) inhibitors. This study assessed mUC treatment patterns in...